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1. Introduction
The virotherapy approach to cancer therapy uses virus particles. It is based on the case reports
since 1950s, which reported the regression of cancers including leukemia, Hodgkin’s disease,
and Burkitt’s lymphoma after the infection of wild type viruses [1-11].
The earliest virotherapies involved injection of wild-type viruses and evaluation of their
efficacies [1-3]. Ex vivo therapies using autologous irradiated tumors infected with oncolytic
viruses were also investigated [12-18]. Deletion mutants of oncolytic viruses [19-24], and
recombinant viruses carrying a therapeutic gene [25-32] that induce cancer apoptosis or cancer
immunity have been developed and evaluated in the clinical setting.
Oncolytic viruses derived from adenovirus, poxvirus, reovirus, picornavirus, paramyxovirus,
and herpes simplex virus are currently available and have been clinically evaluated [33-35]. In
China, two adenovirus-based products (Gendicine and Ocorine) have been commercialized
[36], while randomized phase III studies of two oncolytic viruses (reovirus and poxvirus) are
ongoing in advanced countries [33-35]. Thus, virotherapy is expected to become available as
a new approach for cancer treatment, and specific product approval is anticipated in the US,
EU, and Japan [37].
The major drawback associated with virotherapy is safety since replicating viruses are used
in this therapy. In order to reduce the toxicity to normal cells, oncolytic viruses with strict
specificity for cancer cells were constructed [29, 38-42]. However, the use of these viruses is
still considered to be high risk because it is theoretically possible that a virulent infection may
occur after recombination with wild-type viruses [43].
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An alternative option to avoid such a risk is to use a non-replicating oncolytic virus [44]. We
found that a non-replicating oncolytic virus (HVJ-E: hemagglutinating virus of Japan-
envelope) is able to induce cancer cell-specific apoptosis and immunity [45]. The induction of
apoptosis and activation of dendritic cells in vitro, and anti-tumor activity in vivo are similar
to the wild-type hemagglutinating virus of Japan (also known as Sendai virus, HVJ) [45].
The hemagglutinating virus of Japan was discovered in Sendai, Japan, in the 1950s [46]. It is a
paramyxovirus with a minus-strand RNA genome. The virus has fusogenic activity [47, 48],
and is used to prepare hybridoma cells for the production of monoclonal antibodies, and
heterokaryons for chromosome analysis [49-51].
The hemagglutinating virus of Japan-envelope is an inactivated HVJ particle [52]. It is
manufactured by a process similar to that used for whole virus particle vaccines. Good
manufacturing practice (GMP)-regulated processes have been established in their production
for use in preclinical and clinical studies [53].
We conducted dose-setting efficacy studies for HVJ-E in a murine cancer model in which dose-
dependent anti-cancer activity was observed. We also conducted safety studies following good
laboratory practices (GLP), including pharmacological safety studies and toxicokinetic (TK)
studies in rats and monkeys, as part of an investigational new drug (IND) application.
Osaka University Hospital is currently conducting two investigational clinical studies with
HVJ-E for the treatment of advanced melanoma and castration-resistant prostate cancer
(CRPC) [54-56]. These clinical trials are the first human studies for HVJ-E and will reveal the
safety and efficacy of the non-replicating virus (HVJ-E). Virotherapy with a non-replicating
oncolytic virus is a new approach that is anticipated to provide a new strategy for cancer
therapy.
2. A new strategy for cancer therapy
Most cancers are still incurable and new approaches are required to improve the efficacy of
cancer treatments. However, conventional cancer therapies are problematic.
Chemotherapy with anti-cancer agents is useful in achieving tumor regression. However, the
immune system, which is important in the removal of residual cancer cells, is also suppressed
by these agents (Figure 1). Therefore, surviving cancer cells and cancer stem cells (CSC)
eventually acquire drug resistance, resulting in tumor relapse (Figure 1) [57]. Thus, chemo‐
therapy with cytotoxic drugs does not generally result in the necessary eradication of cancer
cells required for long-term survival.
Immune therapies for cancer offer a new approach to cancer treatment, and several products,
including sipuleucel-T, are currently approved in advanced countries [58, 59]. The aim of these
therapies is the removal of cancers by the immune system. Numerous cancer immune therapies
are currently under evaluation in clinical studies. However, these agents are not potent because
of lack of cytotoxic effect on cancer cells (Figure 1).
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These observations suggest that a two-step strategy is necessary for the eradication of cancer
cells (Figure 1).
During the first step, the direct killing of cancer cells is necessary for reduction of tumor
volume. CSCs are usually resistant to conventional anti-cancer drugs and continue to prolif‐
erate during chemotherapy. Therefore, an agent that targets and kills CSCs is required for
effective cancer treatment.
During the second step, the removal of residual cancer cells (and CSCs) from the body by a
cancer-specific immune response is necessary to avoid relapse of the condition [57]. However,
it is difficult for immune cells to recognize and remove CSCs because they exist as a minority
population within the tumor, and possess a lower antigenicity than differentiated cancer cells
[57]. Oncolytic viruses have the capability of both directly killing cancer cells and inducing
cancer immunity.
It has been reported that several oncolytic viruses have the capability to kill CSCs [60-67]. The
reovirus-based oncolytic virus [61], telomerase-specific oncolytic adenovirus [62], and herpes
simplex virus-based oncolytic viruses (G47Delta and Delta 68H-6) [63, 64] reduced CSCs in
murine models of breast cancer, esophageal cancer, and malignant glioma, respectively. Thus,
a virotherapy approach in patients is expected to kill cancer cells and eradicate cancer cells
including CSCs (Figure 1).
3. Non-replicating virus particles as anti-cancer agents
The use of non-replicating virus particles is a new approach in virotherapy.
A non-replicating virus particle, HVJ-E, is currently being developed as a potential new agent
for the treatment of advanced melanoma and CRPC [44, 55, 56]. It is derived from HVJ, a
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Figure 1. Problems with conventional therapies and a 2-step strategy for cancer treatment. Conventional anti-
cancer therapies are problematic and a 2-step therapeutic strategy is proposed for effective cancer treatment. Viro‐
therapy possesses ideal characteristics for such a 2-step therapy. Problems associated with conventional anti-cancer
drugs and immune therapies, including cancer vaccines, are shown.
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member of the paramyxovirus family (Figure 2). The HVJ-E particle is prepared by inactivating
the wild-type virus (HVJ) by treatment with an alkylating agent and UV irradiation [52, 53].
HVJ-E was originally developed as a drug delivery system (vector) for various biopharma‐
ceuticals such as plasmid DNAs, siRNAs, decoy oligonucleotides, antibody proteins, and anti-
cancer drugs [52, 68-75].
Kurooka and Kaneda discovered that the HVJ-E particle itself displayed anti-cancer effects in
a murine model of colon cancer [45]. Similar to the live (replicating) virus, HVJ-E induced
maturation and differentiation of human and murine dendritic cells (DCs). It also induced
infiltration of immune cells into the tumor tissue followed by activation of cancer cell-specific
cytotoxic T cells. Furthermore, HVJ-E suppressed the function of regulatory T cells (Treg),
which have been reported to be negative regulators of cancer immunity. Thus, HVJ-E activates
cancer immunity, and simultaneously suppresses Treg [45].
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Figure 2. Characteristics and structure of HVJ-E/GEN0101. The characteristics of HVJ-E/GEN0101 are shown on the
left. A schematic structure of the particle is shown on the right.
Fujiwara and Kaneda et al. reported that HVJ-E induced innate immunity [76]. Intratumoral
injection of HVJ-E promoted infiltration and activation of natural killer (NK) cells by the
induction of C-X-C motif chemokine 10 (CXCL10) and type I interferons. When HVJ-E was
injected into the tumor of a murine model of renal cell carcinoma (RCC), NK cells exhibited
cytotoxic activity against the RCC cell line in vivo [76]. The involvement of NK cells in the anti-
tumor effect was also confirmed by showing the depletion of NK cells using an asialo-GM1
antibody [76]. Activated NK cells produced interferon-γ, which induces cancer-specific
cytotoxic T cells [76]. These results indicated that HVJ-E is able to induce both innate and
adaptive immunities.
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In addition to the induction of cancer immunities, HVJ-E has the capability to induce cancer
cell-specific apoptosis. Kawaguchi and Kaneda et al. reported that HVJ-E showed a dose-
dependent, direct killing effect on human prostate cancer cell lines. In contrast, it showed no
suppression of normal human prostate epithelium proliferation [77].
HVJ-E also induced apoptosis of prostate cancer cells in vivo because it showed an anti-tumor
effect in severe combined immunodeficiency (SCID) mice that lack B lymphocyte- and T
lymphocyte-mediated immunities [76, 77]. When NK cells were depleted from SCID mice by
injection of the asialo-GM1 antibody, intratumoral injection of HVJ-E still showed an anti-
tumor effect in a murine model of CRPC [77]. This result suggested that HVJ-E showed a direct
killing activity in vivo. HVJ-E-mediated apoptosis of cancer cells was further confirmed in a
murine model of prostate cancer using a NOD/SCID mouse, which lacks both innate (NK cell-
mediated) and adaptive (antibody and CTL-mediated) immunities [54].
Numerous studies have revealed that the non-replicating HVJ-E particle shows anti-tumor
effects in murine models of renal cell carcinoma, glioma, colon, bladder and CRPCs [45, 76-79].
In contrast, previous studies have reported that the non-replicating oncolytic Newcastle
disease virus (NDV) failed to show an anti-tumor effect in vivo [80, 81]. These results are
inconsistent with results obtained with HVJ-E [45, 76, 77, 79], and the putative reason is the
difference between the number of particles used in the studies. In studies with NDV, 5 × 109
PFU of oncolytic virus were systemically or locally administrated [81], whereas the number of
HVJ-E particles administered was estimated to be higher.
Another possibility is the difference in the capability of the virus to deliver its RNA fragments
to target cancer cells. The Z strain-derived HVJ-E used in our studies has the highest level of
membrane fusion activity [52]. Therefore, it is possible that HVJ-E has the ability to deliver
more RNA component to the target cancer cells than the UV-inactivated NDV particle. The
difference in process of inactivation may be responsible for the activity of non-replicating
oncolytic viruses. The Newcastle disease virus was inactivated by UV irradiation, whereas
HVJ-E was inactivated by a combination of treatment with an alkylating agent and UV
irradiation [53]. Inactivation conditions affect the efficiency of delivery, and strictly regulated
processes are necessary to obtain suitable performance [53].
4. Mode of actions
The major target cells of HVJ-E are cancer cells and dendritic cells (DCs) (Figure 3A) [44, 45, 76].
Treatment of cancer cells with HVJ-E enhanced the expression and activation (cleavage) of
caspases 3, 8, and 9 (Figure 4A) [77], and induced dose-dependent apoptosis of melanoma,
prostate, and other cancer cell lines in vitro (Figure 4B) [77]. Interestingly, no apoptotic effects
were observed on normal epithelial cells derived from murine prostate [54, 77]. Thus, the
apoptotic activity of HVJ-E is considered to be specific to cancer cells [54, 77].
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Figure 3. The mechanism of anti-cancer effects of HVJ-E/GEN0101. A novel type of virotherapy agent (HVJ-E/
GEN0101) has a multi-mode of action that is ideal for 2-step cancer treatment. (A) Target cells and sequential anti-
cancer effects of HVJ-E/GEN0101. (B) Signaling pathway induced by stimulation with HVJ-E/GEN0101. The RIG-I/
MAVS pathway is the major pathway involved. RIG-I is a cytosolic receptor for nucleic acids: it usually functions as a
sensor to recognize viral infection. The nucleic acids in the HVJ-E/GEN0101 particle act as an agonist for RIG-I and in‐
duce cancer cell-specific gene expression followed by the induction of apoptosis.
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Figure 4. HVJ-E/GEN0101 induces apoptosis of human and murine melanoma cells. (A) Induction of caspase ac‐
tivity after treatment of melanoma cells with HVJ-E/GEN0101. Human (A375) and murine (B16/BL6) melanoma cells
were treated with various amounts of HVJ-E/GEN0101, and caspase activities were measured 24 hours later. A dose-
dependent activation was observed. (B) Survival of melanoma cells after treatment with various amounts of HVJ-E/
GEN0101. Human (A375) and murine (B16/BL6) melanoma cells were treated with various amounts of HVJ-E/
GEN0101 and cell survival was measured by WST-8 assay 72 hours later.
Matsushima and Kaneda et al. conducted an investigation to determine the active component
for anti-cancer effects, and identified RNA fragments within the particle [54]. Moreover,
Kaneda et al. analyzed the signaling pathway involved and revealed that retinoic acid inducible
gene-I (RIG-I) is a key factor for signal transduction [44, 54, 77]. Retinoic acid inducible gene-
I is a cytosolic nucleic acid receptor and was originally identified as a sensor that recognizes
infection by single strand RNA viruses [82, 83]. Thus, RIG-I has been recognized as an inducer
of immune response against infected viruses [82-84].
The RNA fragments delivered by HVJ-E bind the helicase domain of RIG-I in the cytoplasm
and change the conformation to unmask the caspase activation and recruitment domain
(CARD) (Figure 3B). After binding with the RNA fragments, RIG-I interacts with the mito‐
chondrial antiviral signaling (MAVS) protein on the mitochondrial membrane (Figure 3B) [84].
The mitochondrial antiviral signaling protein forms a complex with an adaptor protein
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(TRAF3/5), stimulates transcription factors (IRF3 and IRF7), and promotes the expression of
interferon-α and β (Figure 3B) [85, 86]. It also stimulates kinases of regulator protein of
transcription factor NK-κB, resulting in increased expression of cytokines, chemokines, and
other genes (Figure 3B) [45, 54, 76, 77].
It has been reported that the RIG-I/MAVS pathway is activated after cancer cells are treated
with HVJ-E [54]. Transfection of isolated RNA fragments from HVJ-E particle also induced
apoptosis of cancer cells in vitro [54]. Thus, HVJ-E uses a natural oligonucleotide (RNA
fragment from the inactivated virus genome) as an active ingredient, and a natural virus
particle (envelope of HVJ) as a delivery system for a nucleic acid medicine (RNA fragments).
The apoptosis induced by HVJ-E was cancer cell-specific because normal endothelial cells
showed no apoptosis after the treatment with HVJ-E [54, 77].
Involvement of RIG-I in cancer cell-specific apoptosis has also been indicated in ovarian
cancers  and  melanoma.  Kübler  and  Barchet  et  al.  reported  that  the  RIG-I  agonist
(Poly(dAdT)) induced apoptosis and expression of MHC class I molecules in ovarian cancer
cells  [87,  88].  Van  and  Bell  et  al.  also  reported  apoptosis  of  ovarian  cancer  cells  after
treatment with dsRNA [89]. Analysis by shRNA-mediated knockdown revealed that RIG-
I  and other  receptors  for  dsRNA (TLR3 and MDA-5)  were involved in the caspase 8/9-
mediated apoptosis of cancer cells. Similar to sensitivity of HVJ-E, epithelial cells derived
from ovarian surface was resistant to apoptosis mediated by RIG-I signal pathway. When
combined with conventional chemotherapy (carboplatin/paclitaxel), treatment with dsRNA
showed a synergistic suppression of ovarian cancer cell viability [89]. Besch et al.  report‐
ed that stimulation of RIG-I and MDA-5 induced apoptosis of human melanoma cells [90].
The authors used pppRNA and poly(I:C) as ligands for RIG-I and MDA-5, and showed the
involvement of caspase-9 and Apaf-1 during apoptosis. They also reported the reduction
of lung metastasis by treatment with ligands for RIG-I and MDA-5 in the NOD/SCID mouse
[90].  Details  of  the  underlying pathways  are  currently  being analyzed using siRNAs of
apoptosis-related factors [54].  It  has been suggested that differences in the expression of
apoptotic genes such as Noxa, TRAIL, and TRAIL receptors in cancer cells and normal cells
determine the specificity of apoptosis induced by HVJ-E (Figure 3B) [54].
HVJ-E also induced differentiation and maturation of murine and human DCs [45]. It induced
the expression of surface markers on mature DCs, and the production of various cytokines and
chemokines from DCs [45, 76, 77]. Activated DCs induce both innate (NK cell-mediated) and
adaptive (cytotoxic T cell-mediated) immunities (Figure 3A) [45, 76]. It has been reported that
an RIG-I agonist (Poly(dAdT)) induced the production of cytokines (IL-6 and TNF-α) and
chemokines (CXCL1-and CCL5/RANTES) [87, 88] in human ovarian cancer cells.
5. Efficacy in preclinical studies
The  efficacy  of  the  non-replicating  oncolytic  virus  (HVJ-E/GEN0101)  was  examined  in
murine models of melanoma and prostate cancer (Figure 5A). GEN0101 is the identifica‐
tion code for the agent. The data have indicated that the anti-tumor effect is dose-depend‐
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ent similar to other non-viral anti-cancer agents (Figure 5B). This feature is important for
the development of non-replicating oncolytic virus as a novel therapeutic agent; identifica‐
tion of the optimal dose for non-replicating oncolytic viruses is easier than determining the
optimal dose for replicating oncolytic viruses as the latter are subject to change (increase)
resulting from replication in target  cancer cells.  The effects  of  administration in a xeno‐
graft  model  of  human CRPC were also examined (Figure 5A).  Efficacy after  subcutane‐
ous  administration  was  revealed  (Figure  5C).  It  is  known  that  the  SCID  mice  lacks  B
lymphocyte-  and T  lymphocyte-mediated  immunities  such  as  antibody production,  and
induction  of  cytotoxic  T  cells  but  retains  monocytes  and NK cells  important  for  innate
immunity.  Thus,  the  non-replicating  virus  (HVJ-E/GEN0101)  is  able  to  induce  innate
immunity,  and show anti-cancer  activity  in  vivo  even in  the absence of  direct  killing of
cancer cells. Efficacy by subcutaneous administration is important for the development of
a  non-replicating  virus  because  subcutaneous  administration  is  more  common  than
intratumoral  administration.  Intratumoral  administration  kills  cancer  cells  directly  and
promotes the release of tumor antigens, which are recognized by immune cells. Subcutane‐
ous administration is expected to enhance and sustain the immune response. Therefore, the
combination of  intratumoral  and subcutaneous administration is  suggested as a suitable
regimen in the clinical setting.
In summary, the results of efficacy studies have indicated that the anti-cancer effect of the
non-replicating oncolytic virus HVJ-E/GEN0101 is dose-dependent similar to conventional
anti-cancer drugs, and subcutaneous administration may be the preferred administration
route for the viral and non-replicating viral agents.
6. Safety studies
Safety of the non-replicating oncolytic virus (HVJ-E/GEN0101) has been confirmed in non-
primate (rat) and primate (Cynomolgus monkey) animals. Lists of the studies that have been
conducted are shown in Table 1A and B.
Results from single dose general toxicity studies revealed that no death or severe finding was
observed even in the maximum dosage groups. Similar to the single dose studies, no severe
finding was observed in repeated dose, general toxicity studies (Table 1A).
Results from immunological and genetic toxicity studies in rat and monkeys revealed that no
abnormal symptoms related to the test agent were observed. The levels of IL-6 and IFN-γ in
monkey serum were analyzed after subcutaneous injection of HVJ-E/GEN0101, and the levels
of both cytokines were determined to be within the normal range (data not shown). A core
battery of safety pharmaceutical studies was performed to determine the effects on major
organs (central nervous, respiratory, and cardiovascular systems); no abnormal effect was
observed with the exception of transient and non-severe pyrexia (Table 1B).
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Figure 5. Efficacy studies of HVJ-E/GEN0101 in a murine model of melanoma and prostate cancer.(A) Protocols
for the efficacy study using murine models of melanoma and prostate cancer. Left: C57/BL6 mice were transplanted
with B16/BL6 cells and 3 intratumoral injections of HVJ-E/GEN0101 were administered after tumor formation (4 days
after transplant). A time course study of change in tumor volume was performed, and the difference in tumor volume
among the three groups was statistically analyzed at the end of the study. Significant differences were determined by
Dunnett’s multigroup test, and significant differences to the medium (control) group were observed (p < 0.01). The
survival rate after the injection of HVJ-E/GEN0101 was also monitored in the melanoma model. A survival study was
performed and the difference among the three groups was statistically analyzed at the end of the study. Significant
differences were determined by log-rank analysis. Significant differences to the medium group were observed (p <
0.001). Right: Protocol for the efficacy study in a murine model of prostate cancer. Human CRPC (PC-3)-bearing mice
were used for the study. A summary of the study protocol is shown. The anti-tumor effect of HVJ-E/GEN0101 for each
administration route was examined. Severe combined immunodeficiency mice were transplanted with PC-3 cells. Two
intratumoral injections or 6 subcutaneous injections of HVJ-E/GEN0101 were performed after tumor formation (4
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days after transplant). A time course study of change in tumor volume was performed and differences in tumor vol‐
ume between the two groups were statistically analyzed at the end of study. Significant differences were determined
by t-test and significant differences to the medium were observed in both routes (p < 0.01 and p < 0.05). (B) Efficacy
study in a murine model of melanoma. Dose-dependency of the anti-tumor effect of HVJ-E/GEN0101 was revealed.
(C) Efficacy study in a murine model of prostate cancer. A time course study of change in tumor volume was per‐
formed and differences in tumor volume between the two groups were statistically analyzed at the end of the study.
Significant differences were determined by t-test, and significant differences to the medium were observed for both
administration routes (p < 0.01 and p < 0.05).
a) Toxicological study (1): General toxicity study
Dosing Regimen Species Route Dose
Single Dose
Rat iv single
Rat sc single
Cynomolgus monkey iv single
Cynomolgus monkey sc single
Repeated Dose
Rat iv 7 days
Rat sc 6 times in 2 weeks
Cynomolgus monkey sc 6 times in 2 weeks
b) Toxicological study (2): Safety pharmacology and other studies
Study Method Species Route Dose
Safety pharmacology
Rat FOB Rat sc single
Respiratory Rat sc single
Cardiovascular Cynomolgus monkey sc single
TK Q-PCR Rat sc 6 times 2 weeks
Genetic toxicity Micronucleus Rat sc single
Antibody production ELISA Rat sc 6 times 2 weeks
Table 1. Summary of toxicological studies
7. Clinical studies
Two clinical studies using the non-replicating oncolytic virus (HVJ-E/GEN0101) are currently
being conducted in Osaka University Hospital. The target diseases are advanced melanoma
(stage IIIC and stage IV) and CRPC [55, 56]. These proof-of-concept studies in melanoma and
CRPC using the non-replicating oncolytic virus were initiated in July 2009 and July 2011,
respectively [55, 56]. The respective summaries of both studies are shown in Table 2A and B.
The primary endpoints of these studies were safety and tolerability based on the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0, whereas the secondary
endpoints were efficacy and confirmation of the mode of action. The major difference between
the regimens for the melanoma and CRPC studies was the route of administration and number
of administrations. A combination of intratumoral and subcutaneous routes of administration
(one intratumoral and three subcutaneous injections) was adopted in the CRPC study. In
addition, a new injection system developed by Okayama University was used in the CRPC
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study. This system permits stable refrigerated storage of the test article, and accurate injection
into the prostate [91].
a) Advanced melanoma
Study title Phase I/II investigational clinical study of inactivated HVJ-E administration for advanced
malignant melanoma patients
Condition Malignant melanoma ( AJCC stage IIIC or stage IV)
Study design Masking: Open Label
Allocation: Non-Randomized
Primary endpoint: Safety and tolerability
Secondary endpoint: Anti-tumor immunity and validity
Target sample size: 6–12 patients
Route: Intratumoral
Dose: 6 times in 2 weeks/cycle, 2 cycles
Sponsor Osaka University Graduate School of Medicine (Osaka University Hospital)
URL https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type
=summary&recptno=R000002889&language=E
b) Castration-resistant prostate cancer
Study title Phase I/II investigational clinical study to assess safety and efficacy of intratumoral and
subcutaneous injection of HVJ-E to castration-resistant prostate cancer patients
Condition Castration resistant prostate cancer (CRPC)
Study design Masking: Open Label
Allocation: Non-Randomized
Primary endpoint: Safety and tolerability
Secondary endpoint: Anti-tumor immunity and validity
Target sample size: 6–12 patients
Route: Intratumoral × 1 then SC × 3
Dose: 4 times in 2 weeks/cycle, 2 cycles
Sponsor Osaka University Graduate School of Medicine (Osaka University Hospital)
URL https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000007153&language=E
Table 2. Design of investigational clinical studies
8. Discussion and conclusion
The major disadvantages associated with oncolytic viruses are safety concerns because viral
replication could theoretically cause the emergence of new pathogenic viruses [43]. The use of
non-replicating oncolytic viruses is expected to resolve the safety issues associated with
conventional oncolytic viruses because they are unable to replicate in target cells.
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The modes of action underlying the anti-cancer effects of non-replicating virus on cancer
cells  and immune cells  have been analyzed.  One major  signaling pathway is  the RIG-I/
MAVS pathway [54].  RIG-I is  a cytosolic nucleic acid receptor that acts as a sensor that
detects virus infection [82-84]. Similar to wild-type RNA viruses, the non-replicating virus
(HVJ-E) is able to activate the RIG-I/MAVS pathway in DCs and induce both innate and
adapted immunities. The non-replicating virus also activates the RIG-I/MAVS pathway in
cancer  cells  and  induces  cancer  cell-specific  apoptosis.  Genetic  analyses  suggest  that
differences  in  the  expression  of  apoptosis-related  genes  define  the  sensitivity  to  the
treatment  with  a  non-replicating  virus  (HVJ-E)  [54].  Furthermore,  it  is  suggested  that
methylation of the respective enhancer/promoter regions underlies differences in transcrip‐
tion of apoptosis-related genes [54].
RIG-I, TLR3, and MDA-5 signaling pathways are involved in the apoptosis of ovarian cancers
[87-89] and melanoma [90]. Thus, the RIG-I/MAVS pathway is likely to emerge as a new target
for the development of drugs that induce cancer cell-specific apoptosis.
The  non-replicating  virus  (HVJ-E)  activates  DCs  to  produce  IL-6,  which  suppress  the
function  of  Treg  [45].  This  effect  is  expected  to  maintain  the  induced cancer  immunity
because Treg is known to be a negative regulator of immune responses [92-94]. It has been
reported that  cancer  cells  escape  cancer  immunity  by  the  recruitment  and activation  of
Treg.  Therefore,  it  will  be important to control  the function of Treg for long-term effec‐
tive induction and maintenance of cancer immunities. Suzuki and Kaneda et al.  reported
that the RIG-I/MAVS pathway was not required to induce the expression of IL-6 [95]. The
attachment of the HVJ-E particle to the surface of DCs was sufficient for the production of
IL-6,  suggesting that the RNA fragments are unnecessary for the induction of this cyto‐
kine [95]. Detailed analyses identified that the F protein on the surface of HVJ-E is involved
in the production of IL-6 [95]. Binding of the F protein to target cells requires expression
of the HN protein [96]. Several gangliosides, such as GD1a and sialyl paragloboside, are
implicated in the association of the HVJ-E particle and cancer cells because the HN protein
binds the sialic acids of gangliosides. The receptor for the F protein remains unidentified
to  date.  Taken  together,  the  RIG-I/MAVS  signal  pathway,  and  a  second  pathway  that
induces the production of IL-6 may cooperate in the activation and sustainment of cancer
immunity induced by the non-replicating virus (HVJ-E).
The development of a non-replicating oncolytic virus other than HVJ-E is possible because the
manufacturing process for such a particle is similar to that of whole particle viral vaccines. In
case of HVJ-E, the virus is inactivated by treatment with an alkylating agent and UV irradiation,
a process used for the production of vaccines against viral diseases. Thus, the development of
oncolytic viruses could be converted to the development of non-replicating oncolytic particles
by similar manufacturing processes.
A disadvantage associated with non-replicating oncolytic viruses may be the defect in
transmission ability. Therefore, it is possible that a greater amount of non-replicating oncolytic
virus may be required for effective treatment compared with a live oncolytic virus. Alterna‐
tively, more frequent injections may be necessary for complete tumor eradication compared
with the use of live oncolytic viruses. However, it is important to achieve a balance between
A Novel Therapy for Melanoma and Prostate Cancer Using a Non-Replicating Sendai Virus Particle (HVJ-E)
http://dx.doi.org/10.5772/55014
169
the risks and benefits associated with the therapy. In our opinion, repeated administration of
the non-replicating virus should be tolerable because no severe finding was observed during
our safety studies.
In conclusion, non-replicating virus particles such as HVJ-E may resolve the safety issue of
conventional virotherapy and provide a new strategy in cancer treatment.
9. Future perspectives
The first non-replicating oncolytic virus (HVJ-E) is currently under evaluation in clinical
studies. Proof-of-concept data for non-replicating viruses in both clinical and non-clinical
studies are necessary for further development of this approach. Osaka University Hospital is
currently conducting two phase I/IIa studies: one for advanced melanoma and another for
CRPC [55, 56]. The results of these studies will reveal the safety, efficacy, and optimal dosage
regimen necessary for phase II study or randomized, double blind phase III study.
Combination treatment may be an effective approach to increase efficacy [97]. Indeed, an
increase in therapeutic efficacy has been reported for virotherapies combined with photody‐
namic therapy [98, 99], radiotherapy [100], chemotherapy [101, 102], or gene therapy [103].
Kiyohara and Kaneda reported that combination of the non-replicating virus (HVJ-E) and gene
therapy (IL-12) increased efficacy in a murine model of melanoma [104]. Furthermore, it was
reported that a combination of non-replicating virus (HVJ-E) and chemotherapy [bleomycin
or cis-diamminedichloroplatinum (CDDP)] increased efficacy in murine models of colon and
bladder cancers [78, 105].
Technologies for systemic administration and targeting for HVJ-E are under development. The
HN protein of HVJ-E has hemagglutinating activity and causes agglutination and lysis of
erythrocytes in vitro. Currently, inactivation of the HN protein, decreased expression of the
HN protein, and “masking” with platelets is being developed for intravenous injection of HVJ-
E. Targeting after the intravenous injection is also important for systemic delivery. The
addition of transferrin, a single chain antibody, or platelets have been suggested as suitable
modifiers for HVJ-E.
The selection of viruses, or viral strains for the preparation of non-replicating oncolytic viruses
is also important for obtaining higher efficacy because the level of immune response is
dependent on the selection of virus strains [106]. A number of replicating oncolytic viruses are
currently under clinical development [35, 97]. Therefore, it may be feasible to select a suitable
virus for therapeutic application from the oncolytic viruses that have been developed [106,
107]. The tropism and complement resistance features of each virus should be considered for
targeting and stabilization in serum.
HVJ-E is the only non-replicating oncolytic virus currently undergoing clinical investigation.
These studies establish a new strategy for the virotherapy and gene therapy fields. The primary
goal is to provide a novel approach for improving cancer therapy.
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Summary
Conventional cancer therapies suffer from one paradox: although chemotherapeutic agents
strongly kill cancer cells and decrease tumor volume, they simultaneously suppress the
immune system. Chemotherapy frequently results in tumor relapse because residual cancer
cells and cancer stem cells escape immune responses. In contrast, immune therapies including
therapeutic cancer vaccines, effectively induce cancer immunity, but possess weak cytotoxic
activity against cancer cells. Therefore, these treatments usually show weak efficacy. It has
been reported that cancer is able to progress even after the activation and proliferation of
cancer-specific cytotoxic T lymphocytes.
Virotherapy is predicted to become an alternative approach to obtain a model cancer therapy
because it generally displays both oncolytic and immunostimulatory activities. However, the
major drawback associated with current virotherapy is safety concerns. Virotherapy using a
non-replicating virus is a new approach aimed at resolving safety issues. Thus, it is expected
to become a novel concept for cancer therapy in the near future.
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